Role of transport proteins in drug discovery and development: A pharmaceutical perspective

Xenobiotica

Volumn 38, Issue 7-8, 2008, Pages 676-708

  Ayrton, A ^a   Morgan, P ^b  

^a GLAXOSMITHKLINE   (United Kingdom)

^b PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

Author keywords

Brain penetration; Drug discovery and development; Drug drug interactions; Hepatobiliary excretion; Pharmacokinetics; Polymorphisms; Transport proteins

Indexed keywords

ATORVASTATIN; BOSENTAN; CARRIER PROTEIN; CERIVASTATIN; CYCLOSPORIN; DIGOXIN; ENALAPRIL; ERYTHROMYCIN; FEXOFENADINE; FLUINDOSTATIN; GEMFIBROZIL; IRINOTECAN; LOPINAVIR; METHOTREXATE; MEVINOLIN; NATEGLINIDE; OLMESARTAN; PITAVASTATIN; PRAVASTATIN; REPAGLINIDE; RIFAMPICIN; RITONAVIR; ROSIGLITAZONE; ROSUVASTATIN; SIMVASTATIN; TALINOLOL; TEMOCAPRIL; UNINDEXED DRUG; VALSARTAN; VERAPAMIL;

ACTIVE TRANSPORT; AREA UNDER THE CURVE; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG EFFECT; DRUG ELIMINATION; DRUG INDUSTRY; DRUG SAFETY; DRUG TRANSPORT; GENETIC POLYMORPHISM; HUMAN; PROTEIN FUNCTION; PROTEIN TRANSPORT; REVIEW; TISSUE DISTRIBUTION;

ANIMALS; CARRIER PROTEINS; DRUG DESIGN; HUMANS; XENOBIOTICS;

EID: 48749108122     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.1080/00498250801923855     Document Type: Review

References (204)

1. Abe T, Kkakyo M, Tokui T, Nakagomi R, Nishio T, Nakai D, Nomura H, Unno M, Suzuki M, Naitoh T, et al. 1999. Identification of a novel gene family encoding human liver-specific organic anion transporter LST-1. Journal of Biological Chemistry 274:17159-17163.
2. Abel S, Nichols DJ, Brearley CJ, Eve MD. 2000. Effect of cimetidine and ranitidine on pharmacokinetics and pharmacodynamics of a single dose of dofetilide. British Journal of Clinical Pharmacology 49:64-71.
3. Abu-Zahra TN, Wolkoff AW, Kim RB, Pang KS. 2000. Uptake of enalapril and expression of organic anion transporting polypeptide 1 in zonal isolated rat hepatocytes. Drug Metabolism and Disposition 28:801-806.
4. Ando T, Kusuhara H, Merino G, Alvarez AI, Schinkel AH, Sugiyama Y. 2007. Involvement of breast cancer resistance protein (ABCG2) in the biliary excretion mechanism of fluoroquinolones. Drug Metabolism and Disposition 35:1873-1879.
5. Arnadottir M, Eriksson LO, Thysell H, Karkas JD. 1993. Plasma concentration profiles of simvastatin 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase inhibitory activity in kidney transplant recipients with and without ciclosporin. Nephronology 65:410-413.
6. Asberg A, Hartmann A, Fjeldså E, Bergan S, Holdaas H. 2001. Bilateral pharmacokinetic interaction between cyclosporine A and atorvastatin in renal transplant recipients. American Journal of Transplantation 1:382-386.
7. Ayrton A, Morgan P. 2001. Role of transport proteins in drug absorption, distribution and excretion. Xenobiotica 31:469-497.
8. Backman JT, Kyrklund C, Kivisto KT, Wang JS, Neuvonen PJ. 2000. Plasma concentrations of active simvastatin acid are increased by gemfibrozil. Clinical Pharmacology and Therapeutics 68:122-129.
9. Backman JT, Kyrklund C, Neuvonen M, Neuvonen PJ. 2002. Gemfibrozil greatly increases plasma concentrations of cerivastatin. Clinical Pharmacology and Therapeutics 72:685-691.
10. Betts A, Atkinson F, Gardner I, Fox D, Webster R, Beaumont K, Morgan P. 2007. Impact of physicochemical and structural properties on the pharmacokinetics of a series of 1L-adrenoceptor antagonists. Drug Metabolism and Disposition 35:1435-1445.
11. Bi Y-A, Kazolias D, Duignan DB. 2006. Use of cryopreserved human hepatocytes in sandwich culture to measure hepatobiliary transport. Drug Metabolism and Disposition 34:1658-1665.
12. Breedveld P, Zelcer N, Pluim D, Sonmezer O, Tibben MM, Beijnen JH, Schinkel AH, Van Tellingen O, Borst P, Schellens JH. 2004. Mechanism of the pharmacokinetic interaction between methotrexate and benzimidazoles: potential role for breast cancer resistance protein in clinical drug-drug interactions. Cancer Research 64:5804-5811.
13. Brunner M, Langer O, Sunder-Plassmann R, Dobrozemsky G, Muller U, Wadsak W, Krcal A, Karch R, Mannhalter C, Dudczak R, et al. 2005. Influence of functional haplotypes in the drug transporter gene ABCB1 on central nervous system drug distribution in humans. Clinical Pharmacology and Therapeutics 78:182-190.
14. Byrne JA, Strautnieks SS, Mieli-Vergani G, Higgins CF, Linton KJ, Thompson RJ. 2002. The human bile salt export pump: Characterization of substrate specificity and identification of inhibitors. Gastroenterology 123:1649-1658.
15. Campbell SD, De Morais SM, Xu JJ. 2004. Inhibition of human organic anion transporting polypeptide OATP 1B1 as a mechanism of drug-induced hyperbilirubinemia. Chemical and Biological Interactions 150:179-187.
16. Chandra P, Brouwer KLR. 2004. The complexities of hepatic drug transport: current knowledge and emerging concepts. Pharmaceutical Research 21:719-735.
17. Chen C, Hanson E, Watson JW, Lee JS. 2003. P-glycoprotein limits the brain penetration of nonsedating but not sedating H1-antagonists. Drug Metabolism and Disposition 31:312-318.
18. Chen C, Mireles RJ, Campbell SD, Lin J, Mills JB, Xu JJ, Smolarek TA. 2005. Differential interactions of 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors with ABCB1, ABCC2 and OATP1B1. Drug Metabolism and Disposition 33:537-546.
19. Chiou WL, Robbie G, Chung SM, Wu T-C, Ma C. 1998. Correlation of the plasma clearance of 54 extensively metabolised drugs between humans and rats: Mean allometric coefficient of 0.66. Pharmaceutical Research 15:1474-1479.
20. Choo EF, Leake B, Wandel C, Imamura H, Wood AJ, Wilkinson GR, Kim RB. 2000. Pharmacological inhibition of P-glycoprotein transport enhances the distribution of HIV-1 protease inhibitors into brain and testes. Drug Metabolism and Disposition 28:655-660.
21. Chowbray B, Cumaraswamy S, Cheung YB, Zhou Q, Lee Edmund J. 2003. Genetic polymorphisms in MDR1 and CYP3A4 genes in Asians and the influence of MDR1 haplotypes on cyclosporin disposition in heart transplant recipients. Pharmacogenetics 13:89-95.
22. Cooper KJ, Martin PD, Dane AL, Warwick MJ, Raza A, Schneck DW. 2003. Lack of effect of ketoconazole on the pharmacokinetics of rosuvastatin in healthy subjects. British Journal of Clinical Pharmacology 55:94-99.
23. Crettol S, Deglon J-J, Besson J, Croquette-Krokar M, Haemmig R, Gothuey I, Monnat M, Eap CB. 2006. ABCB1 and cytochrome P450 genotypes and phenotypes: Influence on methadone plasma levels and response to treatment. Clinical Pharmacology and Therapeutics 80:668-681.
24. Cui Y, Konig J, Leier I. 2001. Hepatic uptake of bilirubin and its conjugates by human organic anion transporter SLC21A6. Journal of Biological Chemistry 276:9626-9630.
25. Cvetkovic M, Leake B, Fromm MF, Wilkinson GR, Kim RB. 1999. OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. Drug Metabolism and Disposition 27:866-871.
26. De Buck SS, Sinha VK, Fenu LA, Nijsen MJ, Mackie CE, Gilissen RAHJ. 2007. Prediction of human pharmacokinetics using physiologically based modelling; a retrospective analysis of 26 clinically tested drugs. Drug Metabolism and Disposition 35:1766-1780.
27. Dey S. 2006. Single nucleotide polymorphisms in human P-glycoprotein: Its impact on drug delivery and disposition. Expert Opinion in Drug Delivery 391:23-35.
28. Didziapetris R, Japertas P, Adveef A, Petrauskas A. 2003. Classification analysis of P-glycoprotein substrate specificity. Journal of Drug Targetting 11:391-406.
29. Ding R, Tayrouz Y, Riedel KD, Burhenne J, Weiss J, Mikus G, Haefeli WE. 2004. Substantial pharmacokinetic interaction between digoxin and ritonavir in healthy volunteers. Clinical Pharmacology and Therapeutics 76:73-84.
30. Dokoumetzidis A, Kalantzi L, Fotaki N. 2007. Predictive models for oral drug absorption: From in silico methods to integrated dynamic models. Expert Opinion in Drug Metabolism and Toxicology 3:491-505.
31. Doran A, Obach RS, Smith BJ, Hosea NA, Becker S, Callegari E, Chen C, Chen X, Choo E, Cianfrogna J, et al. 2005. The impact of P-glycoprotein on the disposition of drugs targeted for indications of the central nervous system: Evaluation using the MDR1A/1B knockout mouse model. Drug Metabolism and Disposition 33:165-174.
32. Dresser M, Leabman K, Giacomini K. 2001. Transporters involved in elimination of drugs in the kidney: Organic anion transporters and organic cation transporters. Journal of Pharmaceutical Sciences 90:397-421.
33. Edwards JE, Brouwer KR, McNamara PJ. 2002. GF120918, a P-glycoprotein modulator, increases the concentration of unbound amprenavir in the central nervous system in rats. Antimicrobial Agents in Chemotherapy 46:2284-2286.
34. Eichelbaum M, Fromm MF, Schwab M. 2004. Clinical aspects of the MDR1 (ABCB1) gene polymorphism. Therapeutic Drug Monitoring 26:180-185.
35. Ekins S, Andreyev S, Ryabov A, Kirillov E. 2005. Computational prediction of human drug metabolism. Expert Opinion in Drug Metabolism and Toxicology 1:303-324.
36. Endres CJ, Hsiao P, Chung FS, Unadkat JD. 2006. The role of transporters in drug interactions. European Journal of Pharmaceutical Sciences 27:501-517.
37. Fattinger K, Funk C, Pantze M, Weber C, Reichen J, Stieger B, Meier PJ. 2001. The endothelin antagonist bosentan inhibits the canalicular bile salt export pump: A potential mechanism for hepatic adverse reactions. Clinical Pharmacology and Therapeutics 69:223-231.
38. Fellay J, Marzolini C, Meaden ER, Back DJ, Buclin T, Chave J-P, Decosterd LA, Furrer H, Opravil M, Pantaleo G, et al. 2002. Response to antiretroviral treatment in HIV-1 infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study. Lancet 359:30-36.
39. Feng B, Obach R, Burstein A, Clark D, De Morais S, Faessel H. 2007. Effect of human renal cationic transporter inhibition on the pharmacokinetics of varenicline, a new therapy for smoking cessation: An in vitro-in vivo study. Clinical Pharmacology and Therapeutics October 2007. doi:10.1038/sj.clpt. 6100405.
40. Funk C, Pantze M, Jehle L, Ponelle C, Scheuermann G, Lazendic M, Gasser R. 2001. Troglitazone-induced intrahepatic cholestasis by an interference with the hepatobiliary export of bile acids in male and female rats. Correlation with the gender difference in troglitazone sulfate formation and the inhibition of the canalicular bile salt export pump (Bsep) by troglitazone and troglitazone sulfate. Toxicology 167:83-98.
41. Gaedigk A, Bradford DA, Marcussi KA, Leeder JS. 2002. Unique CYP2D6 activity distribution and genotype-phenotype discordance in black Americans. Clinical Pharmacology and Therapeutics 72:76-89.
42. Gao B, Hagenbuch B, Kullak-Ublick GA, Benke D, Aguzzi A, Meier PJ. 2000. Organic anion transporting polypeptides mediate transport of opioid peptides across blood-brain barrier. Journal of Pharmacology and Therapeutics 294:73-79.
43. Gardner IB, Fenner K, Morgan P. 2000. Using the model compound pravastatin to understand in vitro-in vivo correlations for transport proteins. Drug Metabolism Reviews 32(Suppl. 1):55.
44. Gardner IB, Walker DK, Lennard MS, Smith DA, Tucker GT. 1995. Comparison of the disposition of two novel combined thromboxane synthase inhibitors/thromoboxane A2 receptor antagonists in the isolated perfused rat liver. Xenobiotica 25:185-197.
45. Gerloff T, Schaefer M, Johne A, Oselin K, Meisel C, Cascorbi I, Roots I. 2002. MDR1 genotypes do not influence the absorption of a single oral dose of 1mg digoxin in healthy white males. British Journal of Clinical Pharmacology 54:610-616.
46. Gombar VK, Polli JW, Humphreys JE, Wring SA, Serabjit-Singh C. 2004. Predicting P-glycoprotein substrates by quantitative structure-activity relationship model. Journal of Pharmaceutical Sciences 93:957-968.
47. Groothius GM, Hulstaert CE, Kalicharan D, Hardonk MJ. 1981. Plasma membrane specialisation and intracellular polarity of freshly isolated rat hepatocytes. European Journal of Cell Biology 26:43-51.
48. Gurney H, Wong M, Balleine RL, Rivory LP, McLachlan AJ, Hoskins JM, Wilcken N, Clarke CL, Mann GJ, Collins M, et al. 2007. Imatinib disposition and ABCB1 (MDR1, P-glycoprotein) genotype. Clinical Pharmacology and Therapeutics 82:33-40.
49. Hagenbuch B. 2007. Cellular entry of thyroid hormones by organic anion transporting polypeptides. Best Practice Research in Clinical Endocrinology Metabolism 21:209-221.
50. Hagenbuch B, Meier PJ. 2003. The superfamily of organic anion transporting polypeptides. Biochimica et Biophysica Acta 1609:1-18.
51. Hasegawa M, Kusuhara H, Endou H, Sugiyama Y. 2003. Contribution of organic anion transporters to the renal uptake of anion compounds and nucleoside derivatives in rat. Journal of Pharmacology and Experimental Therapeutics 305:1087-1097.
52. Hasegawa M, Kusuhara H, Sugiyama D, Ito K, Ueda S, Endou H, Sugiyama Y. 2002. Functional involvement of rat organic anion transporter 3 (rOat3) in the renal uptake of organic anions. Journal of Pharmacology and Experimental Therapeutics 300:746-753.
53. He G, Massarella J, Ward P. 1999. Clinical pharmacokinetics of the prodrug oseltamivir and its active metabolite Ro 64-0802. Clinical Pharmacokinetics 37:471-484.
54. Hedman A, Angelin B, Arvidsson A, Beck O, Dahlqvist R, Nilsson B, Olsson M, Schenck-Gustafsson K. 1991. Digoxin-verapamil interaction: reduction of biliary but not renal digoxin clearance in humans. Clinical Pharmacology and Therapeutics 49:256-262.
55. Hedman A, Angelin B, Arvidsson A, Dahlqvist R, Nilsson B. 1990. Interactions in the renal and biliary elimination of digoxin: stereoselective difference between quinine and quinidine. Clinical Pharmacology and Therapeutics 47:20-26.
56. Hilgendorf C, Ahlin G, Seithel A, Artursson P, Ungell A-L, Karlsson J. 2007. Expression of thirty six drug transporter genes in human intestine, liver, kidney and organotypic cell lines. Drug Metabolism and Disposition 35:1333-1340.
57. Hill G, Cihlar T, Oo C, Ho ES, Prior K, Wiltshire H, Barrett J, Liu B, Ward P. 2002. The anti-influenza drug oseltamivir exhibits low potential to induce pharmacokinetic drug interactions via renal secretion-correlation of in vivo and in vitro studies. Drug Metabolism and Disposition 30:13-19.
58. Hinderling PH, Hartmann D. 1991. Pharmacokinetics of digoxin and main metabolites/derivatives in healthy humans. Therapeutic Drug Monitoring 13:381-401.
59. Hinton LK, Galetin A, Houston JB. 2007. Multiple inhibition mechanisms and prediction of drug-drug interactions: status of metabolism and transporter models as exemplified by gemfibrozil-drug interactions. Pharmaceutical Research [online 27 September].
60. Hoffmaster KA, Turncliff RZ, LeCluyse EL, Kim RB, Meier PJ, Brouwer KL. 2004. P-glycoprotein expression, localisation and function in sandwich-cultured primary rat and human hepatocytes: relevance to the hepatobiliary disposition of a model opiod peptide. Pharmaceutical Research 21:1294-1302.
61. Hoffmeyer S, Burk O, Von Richter O, Arnold HP, Brockmoller J, Johne A, Cascorbi I, Gerlo T, Roots I, Eichelbaum M, et al. 2000. Functional polymorphisms of the human multidrug resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proceedings of the National Academy of Sciences. USA 97:3473-3478.
62. Hou T, Wang J, Zhang W, Xu X. 2006. Recent advances in computational prediction of drug absorption and permeability in drug discovery. Current Medicinal Chemistry 13:2653-2667.
63. Hsiang B, Zhu Y, Wang Z. 1999. A novel human hepatic organic anion transporting polypeptide (OATP2). Journal of Biological Chemistry 274:37161-37168.
64. Hsiao P, Sasongko L, Link JM, Mankoff DA, Muzi M, Collier AC, Unadkat JD. 2006. Verapamil P-glycoprotein transport across the rat blood-brain barrier: cyclosporine, a concentration inhibition analysis, and comparison with human data. Journal of Pharmacology and Experimental Therapeutics 317:704-710.
65. Huang L, Wang Y, Grimm S. 2006. ATP-dependent transport of rosuvastatin in membrane vesicles expressing breast cancer resistance protein. Drug Metabolism and Disposition 34:738-742.
66. Huang S-M. 2006. Drug interaction studies - study design, data analysis and implications for desing and labelling. FPA draft guidance. http://www.fda.gov/cder/guidance/669dft.htm
67. Igel S, Drescher S, Mürdter T, Hofmann U, Heinkele G, Tegude H, Glaeser H, Brenner SS, Somogyi AA, Omari T, et al. 2007. Increased absorption of digoxin from the human jejunum due to inhibition of intestinal transportermediated efflux. Clinical Pharmacokinetics 46:777-785.
68. Inotsume N, Nishimura M, Nakano M, Fujiyama S, Sato T. 1990. The inhibitory effect of probenecid on renal excretion of famotidine in young, healthy volunteers. Journal of Clinical Pharmacology 30:50-56.
69. Inui KI, Masuda S, Saito H. 2000. Cellular and molecular aspects of drug transport in the kidney. Kidney International 58:944-958.
70. Ishizuka H, Konno K, Naganuma H, Nishimura K, Kouzuki H, Suzuki H, Stieger B, Meier PJ, Sugiyama Y. 1998. Transport of temocaprilat into rat hepatocytes: role of organic anion transporting polypeptide. Journal of Pharmacology and Experimental Therapeutics 287:37-42.
71. Ito K, Suzuki H, Horie T, Sugiyama Y. 2005. Apical/basolateral surface expression of drug transporters and its role in vectorial transport. Pharmaceutical Research 22:1559-1577.
72. Iwanaga T, Nakakariya M, Yabuuchi H, Maeda T, Tamai I. 2007. Involvement of bile salt export pump in flutamide-induced cholestatic hepatitis. Biology and Pharmacology Bulletin 30:739-744.
73. Jaehde U, Sorgel F, Reiter A, Sigl G, Naber KG, Schunack W. 1995. Effect of probenecid on the distribution and elimination of ciprofloxacin in humans. Clinical Pharmacology and Therapeutics 58:532-541.
74. Johne A, Koepke C, Gerlof T, Mai I, Rietbrock S, Meisel C, Hoffmeyer S, Kerb R, Fromm MF, Brinkmann U, et al. 2002. Modulation of steady-state kinetics of digoxin by haplotypes of the P-glycoprotein MDR1 gene. Clinical Pharmacology and Therapeutics 72:584-594.
75. Jones HM, Parrott N, Jorga K, Lave T. 2006. A novel strategy for physiologically based predictions of human pharmacokinetics. Clinical Pharmacokinetics 45:1213-1226.
76. Jonker JW, Smit JW, Brinkhuis RF, Maliepaard M, Beijnen JH, Schellens JH, Schinkel AH. 2000. Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan. Journal of the National Cancer Institute 92:1651-1656.
77. Jorgensen L, Van Beek J, Lund S, Schousboe A, Badolo L. 2007. Evidence of Oatp and Mdr1 in crypopreserved rat hepatocytes. European Journal of Pharmaceutical Sciences 30:181-189.
78. Kaddoumi A, Choi S-U, Kinman L, Whittington D, Tsai C-C, Ho R, Anderson BD, Unadkat JD. 2007. Inhibition of P-glycoprotein activity at the primate blood-brain barrier increases the distribution of nelfinavir into the brain but not into the cerebrospinal fluid. Drug Metabolism and Disposition 35:1459-1462.
79. Kajosaari LI, Laitila J, Neuvonen PJ, Backman JT. 2005. Metabolism of repaglinide by CYP2C8 and CYP3A4 in vitro: effect of fibrates and rifampicin. Basic Clinical Pharmacology and Toxicology 97:249-256.
80. Kajosaari LI, Niemi M, Neuvonen M, Laitila J, Neuvonen PJ, Backman JT. 2005. Cyclosporine markedly raises the plasma concentrations of repaglinide. Clinical Pharmacology and Therapeutics 78:388-399.
81. Kalliokoski A, Neuvonen M, Neuvonen PJ, Niemi M. 2008. No significant effect of SLCO1B1 polymorphism on the pharmacokinetics of rosiglitazone and pioglitazone. British Journal of Clinical Pharmacology 65:78-86.
82. Kameyama Y, Yamashita K, Kobayashi K, Hosokawa M, Chiba K. 2005. Functional characterisation of SLCO1B1 (OATP-C) variants, SLCO1B1*5, SLCO1B1*15 and SLCO1B1*15 + C1007G by using transient expression systems of HeLa and HEK293 cells. Pharmacogenetics and Genomics 15:513-522.
83. Kim RB, Leake BF, Choo EF, Dresser GK, Kubba SV, Schwarz UI, Taylor A, Xie HG, McKinsey J, Zhou S, et al. 2001. Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clinical Pharmacology and Therapeutics 70:189-199.
84. Kimchi-Sarfaty C, Marple AH, Shinar S, Kimchi AM, Scavo D, Roma MI, Kim I-W, Jones A, Arora M, Gribar J, et al. 2007. Ethnicity-related polymorphisms and haplotypes in the human ABCB1 gene. Pharmacogenomics 8:29-39.
85. Koepsell H, Endou H. 2004. The SLC22 drug transporter family. Pflugers Archiv European Journal of Physiology 447:666-676.
86. Konig J, Cui Y, Nies AT, Keppler D. 2000a. A novel human organic anion transporting polypeptide localised to the basolateral hepatocyte membrane. American Journal of Physiology and Gastrointestinal Liver Physiology 278:G156-G164.
87. Konig J, Cui Y, Nies AT, Keppler D. 2000b. Localisation and genomic organisation of a new hepatocellular organic anion transporting polypeptide. Journal of Biological Chemistry 275:23161-23168.
88. Krishnamurthy P, Schuetz JD. 2006. Role of ABCG2/BCRP in biology and medicine. Annual Review of Pharmacology and Toxicology 46:381-410.
89. Kruijtzer CM, Beijnen JH, Rosing H, ten Bokkel Huinink WW, Schot M, Jewell RC, Paul EM, Schellens JH. 2002. Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-glycoprotein inhibitor GF120918. Journal of Clinical Oncology 20:2943-2950.
90. Kullak-Ublick GA, Ismair MG, Stieger B, Landmann L, Huber R, Pizzagalli F, Fattinger K, Meier PJ, Hagenbuch B. 2001. Organic anion transporting polypeptide B (OATPB) and its functional comparison with three other OATPs of human liver. Gastroenterology 120:273-292.
91. Kurzawski M, Bartnicka L, Florczak M, Gornik W, Drozdzik M. 2007. Impact of ABCB1 (MDR1) gene polymorphism and P-glycoprotein inhibitors on digoxin serum concentration in congestive heart failure patients. Pharmacological Reports 59:107-111.
92. Kusuhara H, Sugiyama Y. 2004. Efflux transport systems for organic anions and cations at the blood-CSF barrier. Advanced Drug Delivery Reviews 56:1741-1763.
93. Kyrklund C, Backman JT, Kivistö KT, Neuvonen M, Laitila J, Neuvonen PJ. 2001. Plasma concentrations of active lovastatin acid are markedly increased by gemfibrozil but not by bezafibrate. Clinical Pharmacology and Therapeutics 69:340-345.
94. Kyrklund C, Backman JT, Neuvonen M, Neuvonen PJ. 2003. Gemfibrozil increases plasma pravastatin concentrations and reduces pravastatin renal clearance. Clinical Pharmacology and Therapeutics 73:538-544.
95. Laskin OL, De Miranda P, King DH, Page DA, Longstreth JA, Rocco L, Lietman PS. 1982. Effects of probenecid on the pharmacokinetics and elimination of acyclovir in humans. Antimicrobial Agents in Chemotherapy 21:804-807.
96. Lau YY, Huang Y, Frassetto L, Benet LZ. 2007. Effect of OATP1B transporter inhibition on the pharmacokinetics of atorvastatin in healthy volunteers. Clinical Pharmacology and Therapeutics 81:194-204.
97. Li Y-H, Wang Y-H, Li Y, Yang L. 2006. MDR1 gene polymorphisms and clinical relevance. Acta Genetica Sinica 33:93-104.
98. Liu L, Cui Y, Chung AY, Shitara Y, Sugiyama Y, Keppler D, Pang KS. 2006. Vectorial transport of enalapril by Oatp1a1/Mrp2 and OATP1B1 and OATP1B3/MRP2 in rat and human livers. Journal of Pharmacology and Experimental Therapeutics 318:395-402.
99. Liu X, Chism JP, LeCluyse EL, Brouwer KR, Brouwer KL. 1999. Correlation of biliary excretion in sandwichcultured rat hepatocytes and in vivo in rats. Drug Metabolism and Disposition 27:637-644.
100. Liu X, Smith BJ, Chen C, Callegari E, Becker SL, Chen X, Cianfrogna J, Doran AC, Doran SD, Gibbs JP. 2006. Evaluation of cerebrospinal fluid concentration and plasma free concentration as a surrogate measurement for brain concentration. Drug Metabolism and Disposition 34:1443-1447.
101. Lugo MR, Sharom FJ. 2005. Interaction of LDS-751 with P-glycoprotein and mapping of the location of the R-drug binding site. Biochemistry 44:643-655.
102. Mahar-Doan KM, Humphreys JE, Webster LO, Wring SA, Shampine LJ, Serabjit-Singh C, Adkinson KK, Polli JW. 2002. Passive permeability and P-glycoprotein mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs. Journal of Pharmacology and Experimental Therapeutics 303:1029-1037.
103. Mano Y, Usui T, Kamimura H. 2007. Effects of bosentan, an endothelin receptor antagonist, on bile salt export pump and multidrug resistance- associated protein 2. Biopharmaceutics and Drug Disposition 28:13-18.
104. Martin C, Berridge G, Higgins CF, Mistry P, Charlton P, Callaghan R. 2000. Communication between multiple drug binding sites on P-glycoprotein. Molecular Pharmacology 58:624-632.
105. Marzolini C, Paus E, Buclin T, Kim RB. 2004. Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clinical Pharmacology and Therapeutics 75:13-33.
106. McTaggart F, Buckett L, Davidson R, Holdgate G, McCormick A, Schneck D, Smith G, Warwick M. 2001. Preclinical and clinical pharmacology of Rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. American Journal of Cardiology 87:28B-32B.
107. +/taurocholate cotransporting polypeptide (SLC10A1) and bile salt export pump (ABCB 11)-coexpressing LLC-PK1 cells by cholestasis-inducing drugs. Drug Metabolism and Disposition 34:1575-1581.
108. Mizuno N, Niwa T, Yotsumoto Y, Sugiyama Y. 2003. Impact of drug transporter studies on drug discovery and development. Pharmacological Reviews 55:425-461.
109. Motsinger AA, Ritchie MD, Shafer RW, Robbins GK, Morse GD, Labbe L, Wilkinson GR, Clifford DB, D'Aquila RT, Johnson VA, et al. 2006. Multilocus genetic interactions and response to efavirenz-containing regimens: an Adult AIDS Clinical Trials Group study. Pharmacogenetics and Genomics 16:837-845.
110. Mück W, Mai I, Fritsche L, Ochmann K, Rohde G, Unger S, Johne A, Bauer S, Budde K, Roots I, et al. 1995. Increase in cerivastatin systemic exposure after single and multiple dosing in cyclosporine-treated kidney transplant recipients. Clinical Pharmacology Therapeutics 65:251-261.
111. Murthy GD, Byron D, Shoemaker D, Visweswaraiah H, Pasquale D. 2001. The utility of rifampin in diagnosing Gilbert's syndrome. American Journal Gastroenterology 96:1150-1154.
112. Mwinyi J, Johne A, Bauer S, Roots I, Gerloff T. 2004. Evidence for inverse effects of OATP-C (SLC21A6) 5 and 1b haplotypes on pravastatin kinetics. Clinical Pharmacology and Therapeutics 75:415-421.
113. Nakagomi-Hagihara R, Nakai D, Kawai K, Yoshigae Y, Tokui T, Abe T, Ikeda T. 2006. OATP1B1, OATP1B3 and MRP2 are involved in hepatobiliary transport of olmesartan a novel angiotensin II blocker. Drug Metabolism and Disposition 34:802-809.
114. Nakagomi-Hagihara R, Nakai D, Tokui T, Abe T, Ikeda T. 2007. Gemfibrozil and its glucuronide inhibit the hepatic uptake of pravastatin mediated by OATP1B1. Xenobiotica 37:474-486.
115. Niemi M, Backman JT, Kajosaari LI, Leathart JB, Neuvonen M, Daly AK, Eichelbaum M, Kivistö KT, Neuvonen PJ. 2005a. Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics. Clinical Pharmacology and Therapeutics 77:468-478.
116. Niemi M, Backman JT, Neuvonen M, Neuvonen PJ. 2003. Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics and pharmacodynamics of repaglinide: potentially hazardous interaction between gemfibrozil and repaglinide. Diabetologia 46:347-351.
117. Niemi M, Kivistö KT, Hofmann U, Schwab M, Eichelbaum M, Fromm MF. 2005b. Fexofenadine pharmacokinetics are associated with a polymorphism of the SLCO1B1 gene (encoding OATP1B1) British Journal of Clinical Pharmacology 59:602-604.
118. Niemi M, Pasanen MK, Neuvonen PJ. 2006. SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatin. Clinical Pharmacology and Therapeutics 80:356-366.
119. Niemi M, Schaeffeler E, Lang T, Fromm MF, Neuvonen M, Kyrklund C, Backman JT, Kerb R, Schwab M, Neuvonen PJ, et al. 2004. High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1). Pharmacogenetics 14:429-440.
120. Nishizato Y, Ieiri I, Suzuki H, Kimura M, Kawabata K, Hirota T, Takane H, Irie S, Kusuhara H, Urasaki Y, et al. 2003. Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes: consequences for pravastatin pharmacokinetics. Clinical Pharmacology and Therapeutics 73:554-565.
121. Noe J, Portmann R, Brun ME, Funk C. 2007. Substrate-dependent drug-drug interactions between gemfibrozil, fluvastatin and other organic anion-transporting peptide (OATP) substrates on OATP1B1, OATP2B1, and OATP1B3. Drug Metabolism and Disposition 35:1308-1314.
122. Nozaki Y, Kusuhara H, Kondo T, Iwaki M, Shiroyanagi Y, Nakayama H, Horita S, Nakazawa H, Okano T, Sugiyama Y. 2007. Species difference in the inhibitory effect of nonsteroidal anti-inflammatory drugs on the uptake of methotrexate by human kidney slices. Journal of Pharmacology and Experimental Therapeutics 322:1162-1170.
123. Obach RS, Baxter JG, Liston TE, Silber BM, Jones BC, MacIntyre F, Rance DJ, Wastall P. 1997. The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data. Journal of Pharmacology and Experimental Therapeutics 283:46-58.
124. Ogilvie BW, Zhang D, Li W, Rodrigues AD, Gipson AE, Holsapple J, Toren P, Parkinson A. 2006. Glucuronidation converts gemfibrozil to a potent, metabolism-dependent inhibitor of CYP2C8: implications for drug-drug interactions. Drug Metabolism and Disposition 34:191-197.
125. Ohno Y, Hisaka A, Suzuki H. 2007. General framework for the quantitative prediction of CYP3A4-mediated oral drug interactions based on the AUC increase by coadministration of standard drugs. Clinical Pharmacokinetics 46:681-696.
126. Olbricht C, Wanner C, Eisenhauer T, Kliem V, Doll R, Boddaert M, O'Grady P, Krekler M, Mangold B, Christians U. 1997. Accumulation of lovastatin, but not pravastatin, in the blood of cyclosporine-treated kidney graft patients after multiple doses. Clinical Pharmacology and Therapeutics 62:311-321.
127. Oo C, Barrett J, Hill G, Mann J, Dorr A, Dutkowski R, Ward P. 2001. Pharmacokinetics and dosage recommendations for an oseltamivir oral suspension for the treatment of influenza in children. Paediatric Drugs 3:229-236.
128. Park JW, Siekmeier R, Lattke P, Merz M, Mix C, Schüler S, Jaross W. 2001. Pharmacokinetics and pharmacodynamics of fluvastatin in heart transplant recipients taking cyclosporine. American Journal of Cardiovascular Pharmacology and Therapeutics 6:351-361.
129. Pasanen MK, Fredrikson H, Neuvonen PJ, Niemi M. 2007. Different effects of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and rosuvastatin. Clinical Pharmacology and Therapeutics [online 2 May].
130. Pasanen MK, Neuvonen M, Neuvonen PJ, Niemi M. 2006. SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid. Pharmacogenetics and Genomics 16:873-879.
131. Penzak SR, Shen JM, Alfaro RM, Remaley AT, Natarajan V, Falloon J. 2004. Ritonavir decreases the nonrenal clearance of digoxin in healthy volunteers with known MDR1 genotypes. Therapeutic Drug Monitoring 26:322-330.
132. Pizzagalli F, Hagenbuch B, Stieger B, Klenk U, Folkers G, Meier PJ. 2002. Identification of a novel human organic anion transporting polypeptide as a high affinity throxine transporter. Molecular Endocrinology 16:2283-2296.
133. Polli JW, Baughman TM, Humphreys JE, Jordan KH, Mote AL, Salisbury JA, Tippin TK, Serabjit-Singh CJ. 2003. P-glycoprotein influences the brain concentrations of cetirizine (Zyrtec), a second-generation non-sedating antihistamine. Journal of Pharmaceutical Sciences 92:2082-2089.
134. Polli JW, Jarrett JL, Studenberg SD, Humphreys JE, Dennis SW, Brouwer KR, Woolley JL. 1999. Role of P-glycoprotein on the CNS disposition of amprenavir (141W94), an HIV protease inhibitor. Pharmaceutical Research 16:1206-1212.
135. Polli JW, Wring SA, Humphreys JE, Huang L, Morgan JB, Webster LO, Serabjit-Singh C. 2001. Rational use of in vitro P-glycoprotein assays in drug discovery. Journal of Pharmacology and Experimental Therapeutics 299:620-628.
136. Pritchard JB, Miller DS. 1993. Mechanism-mediated renal secretion of organic anions and cations. Physiological Reviews 73:765-796.
137. Prueksaritanont T, Gorham LM, Ma B, Liu L, Yu X, Zhao JJ. 1997. In vitro metabolism of simvastatin in humans: identification of metabolising enzymes and effect of the drug on hepatic P450s. Drug Metabolism and Disposition 25:1191-1199.
138. Rautio J, Humphreys JE, Webster LO, Balakrishnan A, Keogh JP, Kunta JR, Serabjit-Singh C, Polli JW. 2006. In vitro P-glycoprotein inhibition assays for assessment of clinical drug interaction potential of new drug candidates: a recommendation for probe substrates. Drug Metabolism and Disposition 34:786-792.
139. Rowland M, Tozer TN. 1995. Physiological concepts and kinetics. In: Balado D, editor. Clinical pharmacokinetics: concepts and applications, 3rd ed. Williams & Wilkins, Media Pennsylvania, USA. pp 119-136, 156-183.
140. Sadeque AJ, Wandel C, He H, Shah S, Wood AJ. 2000. Increased drug delivery to the brain by P-glycoprotein inhibition. Clinical Pharmacology Therapeutics 68:231-237.
141. Sakaeda T, Nakamura T, Horinouchi M, Kakumoto M, Ohmoto N, Sakai T, Morita Y, Tamura T, Aoyama N, Hirai M, et al. 2001. MDR1 genotype-related pharmacokinetics of digoxin after single oral administration in healthy Japanese subjects. Pharmaceutical Research 18:1400-1404.
142. Sasaki M, Suzuki H, Aoki J, Ito K, Meier PJ, Sugiyama Y. 2004. Prediction of in vivo biliary clearance from the in vitro transcellular transport of organic anions across a double-transfected Madin-Darby canine kidney II monolayer expressing both rat organic anion transporting polypeptide 4 and multidrug resistance associated protein 2. Molecular Pharmacology 66:450-459.
143. Sasaki M, Suzuki H, Ito K, Abe T, Sugiyama Y. 2002. Transcellular transport of organic anions across a doubletransfected Madin-Darby canine kidney II cell monolayer expressing both human organic anion transporting polypeptide (OATP2/SLC21A6) and multidrug resistance associated protein 2 (MRP2/ABCC2). Journal of Biological Chemistry 277:6497-6503.
144. Scarborough GA. 1995. Drug-stimulated ATPase activity of the human P-glycoprotein. Journal of Bioenergetics and Biomembranes 27:37-41.
145. Schneck DW, Birmingham BK, Zalikowski JA, Mitchell PD, Wang Y, Martin PD, Lasseter KC, Brown CD, Windass AS, Raza A. 2004. The effect of gemfibrozil on the pharmacokinetics of rosuvastatin. Clinical Pharmacology and Therapeutics 75:455-463.
146. Schnikel AH, Wagenaar E, Mol CAAM, Deemter L. 1996. P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. Journal of Clinical Investigation 97:2517-2524.
147. Seelig A, Gerebtzoff G. 2006. Enhancement of drug absorption by noncharged detergents through membrane and P-glycoprotein binding. Expert Opinion in Drug Metabolism and Toxicology 2:733-752.
148. Sharom FJ, Lu P, Liu R, Yu X. 1998. Linear and cyclic peptides as substrates and modulators of P-glycoprotein: peptide binding and effects on drug transport and accumulation. Biochemical Journal 333:621-630.
149. Sharom FJ, Yu X, Lu P, Liu R, Chu JW, Szabo K. 1999. Interaction of the P-glycoprotein multidrug transporter (MDR1) with high affinity peptide chemosensitizers in isolated membranes, reconstituted systems and intact cells. Biochemical Pharmacology 58:571-586.
150. Shen DD, Artru AA, Adkinson KK. 2004. Principles and applicability of CSF sampling for the assessment of CNS delivery and pharmacokinetics. Advanced Drug Delivery Reviews 56:1825-1857.
151. Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP. 1994. Interindividual variations in human liver cytochrome P450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. Journal of Pharmacology and Experimental Therapeutics 270:414-423.
152. Shitara Y, Itoh T, Sato H, Sugiyama Y. 2003. Inhibition of transporter-mediated hepatic uptake as a mechanism for drug-drug interaction between cerivastatin and cyclosporin A. Journal of Pharmacology and Experimental Therapeutics 304:610-616.
153. Shitara Y, Sato H, Sugiyama Y. 2005. Evaluation of drug-drug interactions in the hepatobiliary and renal transport of drugs. Annual Review of Pharmacology and Toxicology 45:689-723.
154. Shitara Y, Sugiyama Y. 2006. Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions. Clinical Pharmacology & Therapeutics 112:71-105.
155. Shu Y, Sheardown SA, Brown C, Owen RP, Zhang S, Castro RA, Ianculescu AG, Yue L, Lo JC, Burchard EG, Brett CM, Giacomini KM. 2007. Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action. Journal of Clinical Investigation 117:1422-1431.
156. Simonson SG, Raza A, Martin PD, Mitchell PD, Jarcho JA, Brown CD, Windass AS, Schneck DW. 2004. Rosuvastatin pharmacokinetics in heart transplant recipients administered an antirejection regimen including cyclosporine. Clinical Pharmacology and Therapeutics 76:167-177.
157. Smith DA, Jones BC. 1992. Speculations on the substrate structure-activity relationship (SSAR) of cytochrome P450 enzymes. Biochemical Pharmacology 44:2089-2104.
158. Smith DA, Van de Waterbeemd H, Walker DK. 2006a. Pharmacokinetics. In: Manhold R, Kubinyi H, Folkers G, editors. Pharmacokinetics and metabolism in drug design. Wiley-VCH, Weinheim, Germany. pp 28-33.
159. Smith DA, Van de Waterbeemd H, Walker DK. 2006b. The Clearance Process. In: Manhold R, Kubinyi H, Folkers G, editors. Pharmacokinetics and metabolism in drug design. Wiley-VCH, Weinheim, Germany. pp 67-68.
160. Smith NF, Achara MR, Desai N, Figg WD, Sparreboom A. 2005. Identification of OATP1B3 as a high-affinity hepatocellular transporter of paclitaxel. Cancer Biology and Therapeutics 4:e5-e8.
161. Smith NF, Figg WD, Sparreboom A. 2005. Role of liver-specific transporters OATP1B1 and OATP1B3 in governing drug elimination. Expert Opinion in Drug Metabolism and Toxicology 1:429-445.
162. Somogyi AA, Barratt DT, Coller JK. 2007. Pharmacogenetics of opioids. Clinical Pharmacology and Therapeutics 81:429-444.
163. Sparreboom A, Gelderblom H, Marsh S, Ahluwalia R, Obach R, Principe P, Twelves C, Verweij J, McLeod HL. 2004. Diflomotecan pharmacokinetics in relation to ABCG2 421C>A genotype. Clinical Pharmacology & Therapeutics 76:38-44.
164. Sparreboom A, Loos WJ, Burger H, Sissung TM, Verweij J, Figg WD, Nooter K, Gelderblom H. 2005. Effect of ABCG2 genotype on the oral bioavailability of topotecan. Cancer Biology and Therapeutics 4:650-658.
165. Sugiyama D, Kusuhura H, Shitara Y, Abe T, Meier PJ, Sekine T, Endou H, Suzuki H, Sugiyama Y. 2001. Characterisation of the efflux transport of 17b-estradiol-D-17b-glucuronide from the brain across the blood-brain barrier. Journal of Pharmacology and Experimental Therapeutics 298:316-322.
166. Tachibana-Iimori R, Tabara Y, Kusuhara H, Kohara K, Kawamoto R, Nakura J, Tokunaga K, Kondo I, Sugiyama Y, Miki T. 2004. Effect of genetic polymorphism of OATP-C (SLCO1B1) on lipid-lowering response to HMG-CoA reductase inhibitors. Drug Metabolism and Pharmacokinetics 19:375-380.
167. Tamai I, Nezu J, Uchino H, Sai Y, Oku A, Shimane M, Tsuji A. 2000. Molecular identification and characterisation of novel members of the human organic anion transporter (OATP) family. Biochemical and Biophysical Research Communications 273:251-260.
168. Tang F, Horie K, Yang JZ, Borchardt RT. 2004. Bidirectional transport of rhodamine 123 and Hoechst 33342 fluorescence probes of the binding sites on P-glycoprotein across MDCK-MDR1 cell monolayers. Journal of Pharmaceutical Sciences 73:1185-1194.
169. Thummel KE, Kunze KL, Shen DD. 1997. Enzyme-catalysed processes of first-pass hepatic and intestinal drug extraction. Advanced Drug Delivery Reviews 27:99-127.
170. Thummel KE, Wilkinson GR. 1998. In vitro and in vivo interactions involving CYP3A. Annual Reviews of Pharmacology and Toxicology 38:389-430.
171. Tirona RG, Leake BF, Merino G, Kim RB. 2001. Polymorphisms in OATP-C: identification of multiple allelic variants associated with altered transport activity among European and African-Americans. Journal of Biological Chemistry 276:35669-35675.
172. Tirona RG, Leake BF, Wolkoff AW, Kim RB. 2003. Human organic anion transporting polypeptide C (SLC21A6) is a major determinant of rifampicin-mediated pregnane X receptor activation. Journal of Pharmacology and Experimental Therapeutics 304:223-228.
173. Trauner M, Boyer JL. 2003. Bile salt transporters: molecular characterization, function, and regulation. Physiological Reviews 83:633-671.
174. Treiber A, Schneiter R, Hausler S, Stieger B. 2007. Bosentan is a substrate of human OATP1B1 and OATP1B3: inhibition of hepatic uptake as the common mechanism of its interactions with cyclosporin A, rifampicin, and sildenafil. Drug Metabolism and Disposition 35:1400-1407.
175. Turncliff RZ, Tian X, Brouwer KL. 2006. Effect of culture conditions on the expression and function of Bsep, Mrp2 and Mdr1a/b in sandwich-cultured rat hepatocytes. Biochemical Pharmacology 71:1520-1529.
176. Umehara K-I, Iwatsubo T, Noguchi K, Kamimura H. 2007. Functional involvement of organic cation transporter 1 (OCT1/Oct1) in hepatic uptake of organic cations in humans and rats. Xenobiotica 37:818-831.
177. Urakami Y, Okuda M, Masuda S, Saito H, Inui KI. 1998. Functional characteristics and membrane localisation of rat multispecific organic cation transporters, OCT1 and OCT2, mediating tubular secretion of cationic drugs. Journal of Pharmacology and Experimental Therapeutics 287:800-805.
178. Uwai Y, Saito H, Inui K. 2000. Interaction between methotrexate and nonsteroidal anti-inflammatory drugs in organic anion transporter. European Journal of Pharmacology 409:31-36.
179. Van Vliet AK, Van Thiel CF, Husiman RH, Moshage H, Yap SH, Cohen LH. 1995. Different effects of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors on sterol synthesis in various human cell types. Biochimica et Biophysica Acta 1254:105-111.
180. Venkatakrishnan K, Tseng E, Nelson FR, Rollema H, French JL, Kaplan IV, Horner WE, Gibbs MA. 2007. Central nervous system pharmacokinetics of the Mdr1 P-glycoprotein substrate CP-615,003: intersite differences and implications for human receptor occupancy projections from cerebrospinal fluid exposures. Drug Metabolism and Disposition 35:1341-1349.
181. Verstuyft C, Schwab M, Schaeffeler E, Kerb R, Brinkmann U, Jaillon P, Funck-Brentano C, Becquemont L. 2003. Digoxin pharmacokinetics and MDR1 genetic polymorphisms. European Journal of Clinical Pharmacology 58:809-812.
182. Wang D, Jonker JW, Kato Y, Kusuhara H, Schinkel AH, Sugiyama Y. 2002a. Involvement of organic cation transporter 1 in the hepatic and intestinal distribution of metformin. Journal of Pharmacology and Experimental Therapeutics 302:510-515.
183. Wang JS, Neuvonen M, Wen X, Backman JT, Neuvonen PJ. 2002b. Gemfibrozil inhibits CYP2C8-mediated cerivastatin metabolism in human liver microsomes. Drug Metabolism and Disposition 30:1352-1356.
184. Wang R, Salem M, Yousef IM, Tuchweber B, Lam P, Childs SJ, Helgason CD, Ackerley C, Phillips MJ, Ling V. 2001. Targeted inactivation of sister of P-glycoprotein gene (spgp) in mice results in nonprogressive but persistent intrahepatic cholestasis. Proceedings of the National Academy of Sciences, USA 98:2011-2016.
185. Wang W, Kari PH, Lu AY, Thomas PE, Guengerich FP, Vyas KP. 1991. Biotransformation of lovastatin: IV. Identification of cytochrome P450 3A proteins as the major enzymes responsible for the oxidative metabolism o lovastatin in rat and human liver microsomes. Archives of Biochemical and Biophysics 290:355-361.
186. Ward KW, Smith BR. 2004. A comprehensive quantitative and qualitative evaluation of extrapolation of intravenous pharmacokinetic parameters from rat, dog and monkey to humans. I. Clearance. Drug Metabolism and Disposition 32:603-611.
187. Webborn PJH, Parker AJ, Denton RL, Riley RJ. 2007. In vitro-in vivo extrapolation of hepatic clearance involving active uptake: theoretical and experimental aspects. Xenobiotica 37:1090-1109.
188. Westphal K, Weinbrenner A, Giessmann T, Stuhr M, Franke G, Zschiesche M, Oertel R, Terhaag B, Kroemer HK, Siegmund W. 2000. Oral bioavailability of digoxin is enhanced by talinolol: evidence for involvement of intestinal P-glycoprotein. Clinical Pharmacology Therapeutics 68:6-12.
189. Wilkinson GR. 2005. Drug metabolism and variability among patients in drug response. New England Journal of Medicine 352:2211-2221.
190. Wolkoff AW, Cohen DE. 2003. Bile acid regulation of hepatic physiology: I. Hepatocyte transport of bile acids. American Journal of Physiology Gastrointestinal Liver Physiology 284:G175-G179.
191. Wrighton SA, Stevens JC. 1992. The human hepatic cytochromes P450 involved in drug metabolism. Critical Reviews in Toxicology 22:1-21.
192. Xu LY, He YJ, Zhang W, Deng S, Li Q, Zhang WX, Liu ZQ, Wang D, Huang YF, Zhou HH, et al. 2007. Organic anion transporting polypeptide-1B1 haplotypes in Chinese patients. Acta Pharmacologica Sinica 28:1693-1697.
193. Yamada A, Maeda K, Kamiyama E, Sugiyama D, Kondo T, Schuetz JD, Adachi Y, Hu Z, Kusuhara H, Sugiyama Y. 2007. Multiple human isoforms of drug transporters contribute to the hepatic and renal transport of olmesartan, a selective antagonist of the angiotensin II AT1 receptor. Drug Metabolism and Disposition [online].
194. Yamagata T, Kusuhara H, Morishita M, Takayama K, Benameur H, Sugiyama Y. 2007. Improvement of the oral drug absorption of topotecan through the inhibition of intestinal xenobiotic efflux transporter, breast cancer resistance protein, by excipients. Drug Metabolism and Disposition 35:1142-1148.
195. + independent multispecific anion transporter mediates active transport of pravastatin into rat liver. American Journal of Physiology 27:G36-G4.
196. Yang J, Jamei M, Rowland Yeo K, Tucker GT, Rostami-Hodjegan A. 2007. Prediction of intestinal first-pass drug metabolism. Current Drug Metabolism 8:676-684.
197. Yasui-Furukori N, Uno T, Sugawara K, Tateishi T. 2005. Different effects of three transporting inhibitors, verapamil, cimetidine, and probenecid, on fexofenadine pharmacokinetics. Clinical Pharmacology Therapeutics 77:17-23.
198. Yokooji T, Murakami T, Yumoto R, Nagai J, Takano M. 2007. Role of intestinal efflux transporters in the intestinal absorption of methotrexate in rats. Journal of Pharmacy and Pharmacology 59:1263-1270.
199. Zaher H, Khan AA, Palandra J, Brayman TG, Yu L, Ware JA. 2006. Breast cancer resistance protein (Bcrp/abcg2) is a major determinant of sulfasalazine absorption and elimination in the mouse. Molecular Pharmacology 3:55-61.
200. Zhang P, Tian X, Chandra P, Brouwer KL. 2005. Role of glycosylation in trafficking of Mrp2 in sandwich-cultured hepatocytes. Molecular Pharmacology 67:1334-1341.
201. Zhang W, Chen BL, Ozdemir V, He YJ, Zhou G, Peng DD, Deng S, Xie QY, Xie W, Xu LY, et al. 2007a. SLCO1B1 521TC functional genetic polymorphism and lipid-lowering efficacy of multiple-dose pravastatin in Chinese coronary heart disease patients. British Journal of Clinical Pharmacology 64:346-352.
202. Zhang W, He YJ, Gan Z, Fan L, Li Q, Wang A, Liu ZQ, Deng S, Huang YF, Xu LY, et al. 2007b. OATP1B1 polymorphism is a major determinant of serum bilirubin level but not associated with rifampicin-mediated bilirubin elevation. Clinical and Experimental Pharmacology and Physiology 34:1240-1244.
203. Zhang W, He YJ, Han CT, Liu ZQ, Li Q, Fan L, Tan ZR, Zhang WX, Yu BN, Wang D, et al. 2006a. Effect of SLCO1B1 genetic polymorphism on the pharmacokinetics of nateglinide. British Journal of Clinical Pharmacology 62:567-572.
204. Zhang W, Yu BN, He YJ, Fan L, Li Q, Liu ZQ, Wang A, Liu YL, Tan ZR, Fen-Jiang, et al. 2006b. Role of BCRP 421C>A polymorphism on rosuvastatin pharmacokinetics in healthy Chinese males. Clinica Chimica Acta 37:99-103.